Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02595918 · ClinicalTrials.gov registry record · Phase 1
Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT02595918: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT02595918 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02595918, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This pilot phase I trial studies the side effects of nivolumab and how well it works in treating patients with high-risk kidney cancer before surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Interventions
- BIOLOGICAL Nivolumab
- PROCEDURE Metastasectomy
- PROCEDURE Nephrectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-05-19 |
| Est. Completion | 2020-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02595918
The ClinicalTrials.gov registry entry for NCT02595918 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT02595918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02595918 about?
NCT02595918 is a clinical study titled "Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery". This pilot phase I trial studies the side effects of nivolumab and how well it works in treating patients with high-risk kidney cancer before surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability ...
What is the current status of trial NCT02595918?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2016-05-19. Estimated completion is 2020-08-01.
What interventions are being tested in trial NCT02595918?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Metastasectomy (PROCEDURE), Nephrectomy (PROCEDURE).
Who is sponsoring clinical trial NCT02595918?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.